The dipeptidyl peptidase IV (DPP-IV) adamantane-based drugs, saxagliptin [13] and vildagliptin [14], are currently used as oral hypoglycemic agents for the treatment of type 2 diabetes. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.